Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 May;34(5):792–795. doi: 10.1128/aac.34.5.792

Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

M J Rybak 1, L M Albrecht 1, J R Berman 1, L H Warbasse 1, C K Svensson 1
PMCID: PMC171693  PMID: 2360818

Abstract

The pharmacokinetics of vancomycin were evaluated in 34 patients (10 burn patients, 14 intravenous drug abusers [IVDA], and 10 controls). Multiple serum samples were drawn following a 1-h vancomycin infusion at steady state over an 8- to 12-h dosing interval. Pharmacokinetic parameters were derived by noncompartmental analysis. There were no significant differences among the groups with respect to age, weight, serum creatinine, volume of distribution, or protein binding. Burn patients had a significantly higher creatinine clearance than did IVDA or controls. Vancomycin clearances averaged 142.8, 98.0, and 67.7 ml/min in burn patients, IVDA, and controls, respectively. The renal clearance of vancomycin was also higher in burn patients than in the other groups. IVDA tended to have a higher vancomycin clearance (31% higher) than did controls, but the difference was not statistically significant. Vancomycin clearance was much higher in burn patients requiring dosage individualization and close monitoring. A considerable amount of vancomycin was eliminated through renal tubular secretion, making dosage predictions based on creatinine clearance more difficult. Further work with IVDA will be needed to determine if they represent a group requiring aggressive vancomycin dosages.

Full text

PDF
792

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman B. H., Taylor E. H., Olsen K. M., Abdel-Malak W., Pappas A. A. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988 Apr;22(4):300–303. doi: 10.1177/106002808802200404. [DOI] [PubMed] [Google Scholar]
  2. Bloedow D. C., Hansbrough J. F., Hardin T., Simons M. Postburn serum drug binding and serum protein concentrations. J Clin Pharmacol. 1986 Feb;26(2):147–151. doi: 10.1002/j.1552-4604.1986.tb02923.x. [DOI] [PubMed] [Google Scholar]
  3. Brater D. C., Bawdon R. E., Anderson S. A., Purdue G. F., Hunt J. L. Vancomycin elimination in patients with burn injury. Clin Pharmacol Ther. 1986 Jun;39(6):631–634. doi: 10.1038/clpt.1986.111. [DOI] [PubMed] [Google Scholar]
  4. Garaud J. J., Regnier B., Inglebert F., Faurisson F., Bauchet J., Vachon F. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):53–57. doi: 10.1093/jac/14.suppl_d.53. [DOI] [PubMed] [Google Scholar]
  5. Garrelts J. C., Peterie J. D. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol Ther. 1988 Jul;44(1):9–13. doi: 10.1038/clpt.1988.105. [DOI] [PubMed] [Google Scholar]
  6. Golper T. A., Noonan H. M., Elzinga L., Gilbert D., Brummett R., Anderson J. L., Bennett W. M. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988 May;43(5):565–570. doi: 10.1038/clpt.1988.74. [DOI] [PubMed] [Google Scholar]
  7. Healy D. P., Polk R. E., Garson M. L., Rock D. T., Comstock T. J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987 Mar;31(3):393–397. doi: 10.1128/aac.31.3.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. King C. H., Creger R. J., Ellner J. J. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrob Agents Chemother. 1985 Mar;27(3):285–290. doi: 10.1128/aac.27.3.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Klastersky J., Van der Auwera P. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections. J Antimicrob Chemother. 1986 Mar;17 (Suppl A):19–24. doi: 10.1093/jac/17.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  10. Loirat P., Rohan J., Baillet A., Beaufils F., David R., Chapman A. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med. 1978 Oct 26;299(17):915–919. doi: 10.1056/NEJM197810262991703. [DOI] [PubMed] [Google Scholar]
  11. Morse G. D., Nairn D. K., Bertino J. S., Jr, Walshe J. J. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit. 1987 Jun;9(2):212–215. doi: 10.1097/00007691-198706000-00015. [DOI] [PubMed] [Google Scholar]
  12. Nivoche Y., Contrepois A., Cremieux A. C., Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther. 1982 Jul;222(1):237–240. [PubMed] [Google Scholar]
  13. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  14. Rodvold K. A., Blum R. A., Fischer J. H., Zokufa H. Z., Rotschafer J. C., Crossley K. B., Riff L. J. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988 Jun;32(6):848–852. doi: 10.1128/aac.32.6.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rybak M. J., Frankowski J. J., Edwards D. J., Albrecht L. M. Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin. Antimicrob Agents Chemother. 1987 Oct;31(10):1461–1464. doi: 10.1128/aac.31.10.1461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sawchuk R. J., Rector T. S. Drug kinetics in burn patients. Clin Pharmacokinet. 1980 Nov-Dec;5(6):548–556. doi: 10.2165/00003088-198005060-00003. [DOI] [PubMed] [Google Scholar]
  17. Smith I. L., Schentag J. J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci. 1984 Feb;73(2):281–282. doi: 10.1002/jps.2600730239. [DOI] [PubMed] [Google Scholar]
  18. Sorrell T. C., Packham D. R., Shanker S., Foldes M., Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):344–350. doi: 10.7326/0003-4819-97-3-344. [DOI] [PubMed] [Google Scholar]
  19. White L. O., Edwards R., Holt H. A., Lovering A. M., Finch R. G., Reeves D. S. The in-vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother. 1988 Nov;22(5):739–745. doi: 10.1093/jac/22.5.739. [DOI] [PubMed] [Google Scholar]
  20. Zaske D. E., Sawchuk R. J., Gerding D. N., Strate R. G. Increased dosage requirements of gentamicin in burn patients. J Trauma. 1976 Oct;16(10):824–828. doi: 10.1097/00005373-197610000-00014. [DOI] [PubMed] [Google Scholar]
  21. Zaske D. E., Sawchuk R. J., Strate R. G. The necessity of increased doses of amikacin in burn patients. Surgery. 1978 Nov;84(5):603–608. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES